Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 7.21 as of Wednesday, August 5, 2026.
Forward PE Ratio (7.21) = Close Price ($17.65) / Consensus Forward EPS ($2.45)
FORWARD PE RATIO
7.21
SECTOR MEDIAN · HEALTHCARE
19.59
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-63.20%
vs the sector median at left
Viatris Inc.
Market Cap
$20.55B
Forward PE Ratio
7.21
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Viatris Inc. (VTRS) | $20.55B | 7.21 |
| United Therapeutics Corporation (UTHR)vs › | $22.03B | 18.62 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.99B | 11.29 |
| Moderna, Inc. (MRNA)vs › | $22.32B | N/A |
| STERIS plc (STE)vs › | $22.68B | 22.83 |
| BioNTech SE (BNTX)vs › | $23.16B | N/A |
| Hologic, Inc. (HOLX)vs › | $16.97B | 17.21 |
| Incyte Corporation (INCY)vs › | $24.28B | 25.10 |
| Medpace Holdings, Inc. (MEDP)vs › | $16.41B | 32.67 |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.72B | 39.00 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
7.2
consensus next-FY EPS
At today's $17.65 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.45 | $2.42 – $2.49 | 5 | 7.2x |
| 2027-12-31 | $2.63 | $2.56 – $2.71 | 5 | 6.7x |
| 2028-12-31 | $2.85 | $1.76 – $3.94 | 2 | 6.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
